Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.

ABSTRACT:

Objective

Diabetes is the leading cause of nontraumatic lower-extremity amputations (LEAs). Identification of patients with foot ulcers at risk for amputation remains clinically challenging. Plasma copeptin, a surrogate marker of vasopressin, is associated with the risk of cardiovascular and renal complications in diabetes.

Research design and methods

We assessed the association between baseline plasma copeptin and risk of LEA during follow-up in four cohorts of people with type 1 (GENESIS, n = 503, and GENEDIAB, n = 207) or type 2 diabetes (DIABHYCAR, n = 3,101, and SURDIAGENE, n = 1,452) with a median duration of follow-up between 5 and 10 years. Copeptin concentration was measured in baseline plasma samples by an immunoluminometric assay.

Re

SUBMITTER: Potier L 

PROVIDER: S-EPMC6973542 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature